
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
20 September 2021
Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival
Leading UK leukaemia charities Leukaemia Care and Leukaemia UK have announced a new collaboration to increase awareness of the signs and symptoms of leukaemia and drive improvements in the diagnosis of the disease. The campaign, Spot Leukaemia, is running throughout September – Blood Cancer Awareness Month.
18 July 2021
Open letter from cancer charities to the public
40 charities and organisations have written an open letter, urging the public to help keep vulnerable people safe as restrictions ease.
11 January 2019
Myelofibrosis: Finding new ways to treat patients
Dr Edwin Chen, University of Leeds and John Goldman Fellow
11 January 2019
Lymphoma: Understanding relapse and treatment resistance
Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder